<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877081</url>
  </required_header>
  <id_info>
    <org_study_id>AKI and Probiotics</org_study_id>
    <nct_id>NCT03877081</nct_id>
  </id_info>
  <brief_title>Effect of Probiotics and Prebiotics in Renal Function in Septic Acute Kidney Injury Patients</brief_title>
  <official_title>Effect of Probiotics and Prebiotics in Renal Function in Septic Acute Kidney Injury Patients, Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Civil de Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Civil de Guadalajara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic acute kidney injury is a condition associated with highly related to inflammatory
      molecules. Prebiotics and probiotics have shown to improve inflammatory cascade in animal
      model; In this study, the investigators propose the use of probiotics to improve the clinical
      evolution of septic acute kidney injury patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute kidney injury is most commonly caused by sepsis, where endotoxemia and an expanding
      inflammatory reaction play a key role in its pathogenesis, when this condition is present it
      is highly related to poor clinical outcomes and higher mortality rates. There is no current
      specific treatment, and the therapeutic approach is more orientated to complication
      management. In this study, the investigators propose the use of probiotics to improve the
      clinical evolution of septic acute kidney injury patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2019</start_date>
  <completion_date type="Anticipated">January 4, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 4, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>7 days</time_frame>
    <description>Number of participants with significative reduction of serum creatinine concentration from beginning of the intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>7 days</time_frame>
    <description>Number of defunctions among the subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>7 days</time_frame>
    <description>Number of participants that initiate renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final creatinine</measure>
    <time_frame>7 days</time_frame>
    <description>Last recorded serum creatinine concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary output (final)</measure>
    <time_frame>7 days</time_frame>
    <description>Quantification of urinary output in ml/Kg/hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shock days</measure>
    <time_frame>7 days</time_frame>
    <description>Use of vasopressor therapy during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recuperation of basal creatinine</measure>
    <time_frame>7 days</time_frame>
    <description>Serum creatinine reduction to 25% from basal creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>7 days</time_frame>
    <description>Days of hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Probiotics</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Probiotics. Intervention patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This patients will receive 2 doses of oral probiotics a day, for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This patients will receive 2 doses of oral placebo a day, for seven days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>Administration of oral probiotics with 2 doses a day</description>
    <arm_group_label>Probiotics. Intervention patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of oral placebo with 2 doses a day</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sepsis by SOFA

          -  Acute kidney injury by KDIGO

        Exclusion Criteria:

          -  No presence of sepsis

          -  No presence of AKI

          -  Age below 18 years

          -  Inability or contraindication for oral capsules or probiotics by nasogastric tube
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HCG</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44240</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Samuel Chavez</last_name>
      <phone>3313299609</phone>
      <email>jonarchi_10@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan S Chavez-Iniguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillermo Garcia-Garcia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W, Vanholder R. Acute kidney injury: an increasing global concern. Lancet. 2013 Jul 13;382(9887):170-9. doi: 10.1016/S0140-6736(13)60647-9. Epub 2013 May 31. Review.</citation>
    <PMID>23727171</PMID>
  </reference>
  <reference>
    <citation>Siew ED, Davenport A. The growth of acute kidney injury: a rising tide or just closer attention to detail? Kidney Int. 2015 Jan;87(1):46-61. doi: 10.1038/ki.2014.293. Epub 2014 Sep 17. Review.</citation>
    <PMID>25229340</PMID>
  </reference>
  <reference>
    <citation>Murugan R, Karajala-Subramanyam V, Lee M, Yende S, Kong L, Carter M, Angus DC, Kellum JA; Genetic and Inflammatory Markers of Sepsis (GenIMS) Investigators. Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int. 2010 Mar;77(6):527-35. doi: 10.1038/ki.2009.502. Epub 2009 Dec 23.</citation>
    <PMID>20032961</PMID>
  </reference>
  <reference>
    <citation>Nisula S, Kaukonen KM, Vaara ST, Korhonen AM, Poukkanen M, Karlsson S, Haapio M, Inkinen O, Parviainen I, Suojaranta-Ylinen R, Laurila JJ, Tenhunen J, Reinikainen M, Ala-Kokko T, Ruokonen E, Kuitunen A, Pettilä V; FINNAKI Study Group. Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. Intensive Care Med. 2013 Mar;39(3):420-8. doi: 10.1007/s00134-012-2796-5. Epub 2013 Jan 5. Erratum in: Intensive Care Med. 2013 Apr;39(4):798.</citation>
    <PMID>23291734</PMID>
  </reference>
  <reference>
    <citation>Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant. 2008 Apr;23(4):1203-10. Epub 2007 Oct 25.</citation>
    <PMID>17962378</PMID>
  </reference>
  <reference>
    <citation>Ostermann M, Chang RW. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med. 2007 Aug;35(8):1837-43; quiz 1852.</citation>
    <PMID>17581483</PMID>
  </reference>
  <reference>
    <citation>Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10(3):R73. Epub 2006 May 12.</citation>
    <PMID>16696865</PMID>
  </reference>
  <reference>
    <citation>Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honoré PM, Joannes-Boyau O, Joannidis M, Korhonen AM, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Vidal Andrade E, Webb S, Kellum JA. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015 Aug;41(8):1411-23. doi: 10.1007/s00134-015-3934-7. Epub 2015 Jul 11.</citation>
    <PMID>26162677</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006 Feb;34(2):344-53.</citation>
    <PMID>16424713</PMID>
  </reference>
  <reference>
    <citation>Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011 Jun;79(12):1361-9. doi: 10.1038/ki.2011.42. Epub 2011 Mar 23.</citation>
    <PMID>21430640</PMID>
  </reference>
  <reference>
    <citation>Wang HE, Muntner P, Chertow GM, Warnock DG. Acute kidney injury and mortality in hospitalized patients. Am J Nephrol. 2012;35(4):349-55. doi: 10.1159/000337487. Epub 2012 Apr 2.</citation>
    <PMID>22473149</PMID>
  </reference>
  <reference>
    <citation>Zarjou A, Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol. 2011 Jun;22(6):999-1006. doi: 10.1681/ASN.2010050484. Epub 2011 May 12. Review.</citation>
    <PMID>21566052</PMID>
  </reference>
  <reference>
    <citation>Gomez H, Ince C, De Backer D, Pickkers P, Payen D, Hotchkiss J, Kellum JA. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2014 Jan;41(1):3-11. doi: 10.1097/SHK.0000000000000052. Review.</citation>
    <PMID>24346647</PMID>
  </reference>
  <reference>
    <citation>Mehta RL, Bouchard J, Soroko SB, Ikizler TA, Paganini EP, Chertow GM, Himmelfarb J; Program to Improve Care in Acute Renal Disease (PICARD) Study Group. Sepsis as a cause and consequence of acute kidney injury: Program to Improve Care in Acute Renal Disease. Intensive Care Med. 2011 Feb;37(2):241-8. doi: 10.1007/s00134-010-2089-9. Epub 2010 Dec 9.</citation>
    <PMID>21152901</PMID>
  </reference>
  <reference>
    <citation>Peters E, Antonelli M, Wittebole X, Nanchal R, François B, Sakr Y, Vincent JL, Pickkers P. A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from The Intensive Care Over Nations audit. Crit Care. 2018 Aug 3;22(1):188. doi: 10.1186/s13054-018-2112-z.</citation>
    <PMID>30075798</PMID>
  </reference>
  <reference>
    <citation>Bellomo R, Kellum JA, Ronco C, Wald R, Martensson J, Maiden M, Bagshaw SM, Glassford NJ, Lankadeva Y, Vaara ST, Schneider A. Acute kidney injury in sepsis. Intensive Care Med. 2017 Jun;43(6):816-828. doi: 10.1007/s00134-017-4755-7. Epub 2017 Mar 31. Review.</citation>
    <PMID>28364303</PMID>
  </reference>
  <reference>
    <citation>Gómez H, Kellum JA. Sepsis-induced acute kidney injury. Curr Opin Crit Care. 2016 Dec;22(6):546-553. Review.</citation>
    <PMID>27661757</PMID>
  </reference>
  <reference>
    <citation>Dellepiane S, Marengo M, Cantaluppi V. Detrimental cross-talk between sepsis and acute kidney injury: new pathogenic mechanisms, early biomarkers and targeted therapies. Crit Care. 2016 Mar 15;20:61. doi: 10.1186/s13054-016-1219-3. Review.</citation>
    <PMID>26976392</PMID>
  </reference>
  <reference>
    <citation>Mariano F, Cantaluppi V, Stella M, Romanazzi GM, Assenzio B, Cairo M, Biancone L, Triolo G, Ranieri VM, Camussi G. Circulating plasma factors induce tubular and glomerular alterations in septic burns patients. Crit Care. 2008;12(2):R42. doi: 10.1186/cc6848. Epub 2008 Mar 25.</citation>
    <PMID>18364044</PMID>
  </reference>
  <reference>
    <citation>Pickkers P, Ostermann M, Joannidis M, Zarbock A, Hoste E, Bellomo R, Prowle J, Darmon M, Bonventre JV, Forni L, Bagshaw SM, Schetz M. The intensive care medicine agenda on acute kidney injury. Intensive Care Med. 2017 Sep;43(9):1198-1209. doi: 10.1007/s00134-017-4687-2. Epub 2017 Jan 30. Review.</citation>
    <PMID>28138736</PMID>
  </reference>
  <reference>
    <citation>Cigarran Guldris S, González Parra E, Cases Amenós A. Gut microbiota in chronic kidney disease. Nefrologia. 2017 Jan - Feb;37(1):9-19. doi: 10.1016/j.nefro.2016.05.008. Epub 2016 Aug 21. Review. English, Spanish.</citation>
    <PMID>27553986</PMID>
  </reference>
  <reference>
    <citation>Vanholder R, Glorieux G. The intestine and the kidneys: a bad marriage can be hazardous. Clin Kidney J. 2015 Apr;8(2):168-79. doi: 10.1093/ckj/sfv004. Epub 2015 Feb 10.</citation>
    <PMID>25815173</PMID>
  </reference>
  <reference>
    <citation>Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr Med Res Opin. 2009 Aug;25(8):1919-30. doi: 10.1185/03007990903069249.</citation>
    <PMID>19558344</PMID>
  </reference>
  <reference>
    <citation>Icaza-Chávez ME. [Gut microbiota in health and disease]. Rev Gastroenterol Mex. 2013 Oct-Dec;78(4):240-8. doi: 10.1016/j.rgmx.2013.04.004. Epub 2013 Nov 28. Review. Spanish.</citation>
    <PMID>24290319</PMID>
  </reference>
  <reference>
    <citation>Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013 Feb;83(2):308-15. doi: 10.1038/ki.2012.345. Epub 2012 Sep 19.</citation>
    <PMID>22992469</PMID>
  </reference>
  <reference>
    <citation>Natarajan R, Pechenyak B, Vyas U, Ranganathan P, Weinberg A, Liang P, Mallappallil MC, Norin AJ, Friedman EA, Saggi SJ. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. Biomed Res Int. 2014;2014:568571. doi: 10.1155/2014/568571. Epub 2014 Jul 24.</citation>
    <PMID>25147806</PMID>
  </reference>
  <reference>
    <citation>Miranda Alatriste PV, Urbina Arronte R, Gómez Espinosa CO, Espinosa Cuevas Mde L. Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr Hosp. 2014 Mar 1;29(3):582-90. doi: 10.3305/nh.2014.29.3.7179.</citation>
    <PMID>24559003</PMID>
  </reference>
  <reference>
    <citation>Koppe L, Mafra D, Fouque D. Probiotics and chronic kidney disease. Kidney Int. 2015 Nov;88(5):958-66. doi: 10.1038/ki.2015.255. Epub 2015 Sep 16. Review.</citation>
    <PMID>26376131</PMID>
  </reference>
  <reference>
    <citation>Wanchai K, Pongchaidecha A, Chatsudthipong V, Chattipakorn SC, Chattipakorn N, Lungkaphin A. Role of Gastrointestinal Microbiota on Kidney Injury and the Obese Condition. Am J Med Sci. 2017 Jan;353(1):59-69. doi: 10.1016/j.amjms.2016.11.019. Epub 2016 Nov 17. Review.</citation>
    <PMID>28104104</PMID>
  </reference>
  <reference>
    <citation>Yoshifuji A, Wakino S, Irie J, Tajima T, Hasegawa K, Kanda T, Tokuyama H, Hayashi K, Itoh H. Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats. Nephrol Dial Transplant. 2016 Mar;31(3):401-12. doi: 10.1093/ndt/gfv353. Epub 2015 Oct 20.</citation>
    <PMID>26487672</PMID>
  </reference>
  <reference>
    <citation>Taki K, Takayama F, Niwa T. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr. 2005 Jan;15(1):77-80.</citation>
    <PMID>15648012</PMID>
  </reference>
  <reference>
    <citation>Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S142-5.</citation>
    <PMID>12612972</PMID>
  </reference>
  <reference>
    <citation>Ando Y, Miyata Y, Tanba K, Saito O, Muto S, Kurosu M, Homma S, Kusano E, Asano Y. [Effect of oral intake of an enteric capsule preparation containing Bifidobacterium longum on the progression of chronic renal failure]. Nihon Jinzo Gakkai Shi. 2003;45(8):759-64. Japanese.</citation>
    <PMID>14737993</PMID>
  </reference>
  <reference>
    <citation>Ogawa T, Shimada M, Nagano N, Ito K, Ando T, Shimomura Y, Ando Y, Otsuka K. Oral administration of Bifidobacterium longum in a gastro-resistant seamless capsule decreases serum phosphate levels in patients receiving haemodialysis. Clin Kidney J. 2012 Aug;5(4):373-4. doi: 10.1093/ckj/sfs072.</citation>
    <PMID>25874106</PMID>
  </reference>
  <reference>
    <citation>Yang J, Summanen PH, Henning SM, Hsu M, Lam H, Huang J, Tseng CH, Dowd SE, Finegold SM, Heber D, Li Z. Xylooligosaccharide supplementation alters gut bacteria in both healthy and prediabetic adults: a pilot study. Front Physiol. 2015 Aug 7;6:216. doi: 10.3389/fphys.2015.00216. eCollection 2015.</citation>
    <PMID>26300782</PMID>
  </reference>
  <reference>
    <citation>Finegold SM, Li Z, Summanen PH, Downes J, Thames G, Corbett K, Dowd S, Krak M, Heber D. Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota. Food Funct. 2014 Mar;5(3):436-45. doi: 10.1039/c3fo60348b.</citation>
    <PMID>24513849</PMID>
  </reference>
  <reference>
    <citation>Kellum JA, Lameire N; KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013 Feb 4;17(1):204. doi: 10.1186/cc11454. Review.</citation>
    <PMID>23394211</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Civil de Guadalajara</investigator_affiliation>
    <investigator_full_name>Jonathan Samuel Chavez Iñiguez</investigator_full_name>
    <investigator_title>MD, Nephrologist, Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Acute kidney injury</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

